[Long-term effect of alufibrate in various types of hyperlipidaemia (author's transl)].
D000328:Adult; D000368:Aged; D000535:Aluminum / Q000627:therapeutic use; D002784:Cholesterol / Q000097:blood; D002986:Clinical Trials as Topic; D002994:Clofibrate / Q000627:therapeutic use*; D002995:Clofibric Acid / Q000031:analogs & derivatives; D004341:Drug Evaluation; D004361:Drug Tolerance; D005260:Female; D006801:Humans; D006949:Hyperlipidemias / Q000145:classification / Q000188:drug therapy*; D008055:Lipids / Q000097:blood; D008074:Lipoproteins / Q000097:blood; D008297:Male; D008875:Middle Aged; D010743:Phospholipids / Q000097:blood; D013997:Time Factors; D014280:Triglycerides / Q000097:blood
D008055:Lipids; D008074:Lipoproteins; D010743:Phospholipids; D014280:Triglycerides; C005681:alfibrate; D002995:Clofibric Acid; D002784:Cholesterol; D000535:Aluminum; D002994:Clofibrate
Die Langzeitwirkung von Alufibrat bei verschiedenen Hyperlipidämie-Typen